Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Alpesh Amin

Hospital Medicine · UCI

View

Dr. Akua Ampadu

Hospital Medicine · NYP Weill Cornell

View

Dr. Reza Manesh

Hospital Medicine · Greater Los Angeles VA

View

Dr. Michael Calavano

Hospital Medicine · NYP Weill Cornell

View

Dr. Nasim Afsar

Hospital Medicine

View

Dr. Sara Murray

Hospital Medicine · Johns Hopkins Medicine

View

Dr. Robert Korom

Hospital Medicine · Penda Health

View

Dr. Sunil Kripalani

Hospital Medicine · VUMC

View

Dr. Ronald Greeno

Hospital Medicine · Society of Hospital Medicine

View

Dr. Moises Auron

Hospital Medicine · Cleveland Clinic

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Clinical characteristics and risk factors for Clostridioides difficile infection in the hematopoietic cell transplantation population.

    Nov 14, 2025DOI: 10.1017/ice.2025.10330Journal ArticleICHE

    Written by: Joseph O'BrienBetty HamiltonMatthew A PappasAbhishek Deshpande

    Find these authors on Roon

    MP
    Dr. Matthew Pappas
    Hospital Medicine · Cleveland Clinic

    Summary

    BACKGROUND: Recipients of hematopoietic cell transplantation (HCT) are at increased risk for Clostridioides difficile infection (CDI) and its recurrence, which are associated with significant morbidity. We aimed to characterize risk factors for primary and recurrent CDI in a large cohort of HCT recipients.METHODS: We conducted a retrospective cohort study of 2725 adults who underwent HCT from 2010-2023 to evaluate the epidemiology, timing, and risk factors for CDI. We compared patients who developed CDI with those who did not, adjusting for patient demographics, comorbidities, transplant factors, medications, and laboratory values. Among patients who developed CDI, we investigated risk factors for recurrent CDI.RESULTS: The cumulative 1-year incidence of CDI was 17.8% among allogeneic HCT recipients (181/1016) and 4.1% among autologous recipients (71/1709). Overall CDI incidence increased by 1.4% annually during the study period (95%CI: 1.24-1.53%). Independent risk factors for primary CDI included penicillin antibiotics (aOR 1.51; 95%CI: 1.13-2.02), prior chemotherapy (aOR 8.36; 95%CI: 2.95-23.69 for 1-3 regimens), and umbilical cord blood stem cells (aOR 1.95; 95%CI: 1.07-3.57). Autologous HCT was associated with decreased risk. Among 252 patients with primary CDI, 22 (8.7%) developed recurrence. Macrolide use before index CDI (aOR 7.25; 95%CI: 1.80-29.2) and allogeneic HCT (aOR 31.04; 95%CI: 1.37-731.58) were associated with recurrence.CONCLUSION: CDI is a common, early complication of HCT particularly among allogeneic recipients. Penicillin exposure, prior chemotherapy, and cord blood stem cell source are key risk factors, while macrolide use is associated with recurrence. Our findings highlight potential targets for risk-stratified prevention strategies.
    MPDr. Matthew Pappas

    Dr. Matthew Pappas

    Internal Medicine · Hospital Medicine
    Cleveland Clinic
    matthewp